Solventum CorporationNYSE: SOLV
Health Care · Health Care Technology
$67.06
-0.45%
Vol: 881K
Research Digest
Friday, May 1, 2026
Trian activist pressure escalates with cost-cutting and divestiture demands; Q1 May 5
Trian Fund Management released open letter April 29 criticizing Solventum's post-spin performance, saying management wiped out $13B in shareholder value (market cap only $12B vs expected $25B at spin). Demands: right-size overhead, divest non-core assets (especially Health Information Systems), prioritize buybacks. CEO compensation exceeded $80M in 2+ years with zero shareholder return. Stock at $66.83, down 16% YTD, near 52-week low $62.38. Analyst consensus Buy with $89.4 PT (+33.67% upside). Q1 earnings May 5. Activist risk elevated.
Previous Market Intelligence
13 daysApr 30Trian Fund pushes Solventum to separate dental products and software divisions; shares rise 1.7%Positive▶
Activist investor Trian, holding ~5% stake in Solventum (SOLV), pressured the company on April 30 to separate its dental products and software divisions. The push sent shares up 1.7%. Meanwhile, analyst firms adjusted price targets: Piper Sandler lowered to $92 from $98 on April 17, while BTIG cut to $89 from $100 on April 13. The company is expanding with a $200M R&D facility in Eagan and $220M Brookings facility investment. Q1 earnings due May 5.
Apr 16Solventum to report Q1 2026 earnings on May 5, with J.P. Morgan maintaining Buy ratingPositive▶
Solventum (SOLV) announced its first quarter fiscal 2026 earnings call scheduled for May 5, 2026. J.P. Morgan recently gave the company a Buy rating in April 2026. Recent company developments include Q4 2025 earnings with 2026 guidance and completion of the Acera Surgical acquisition. Analysts hold an average Buy rating with a 12-month target of $90.7, representing 39% upside.
Apr 15BTIG lowered Solventum price target to $89 on April 13; J.P. Morgan gave Buy rating April 8; Q1 earnings May 5.Mixed▶
BTIG lowered Solventum's price target to $89 from $100 on April 13, offsetting a Buy rating from J.P. Morgan on April 8. Solventum will report Q1 fiscal 2026 earnings on May 5 after market close. The company completed the $725M acquisition of Acera Surgical on December 23, 2025. Q4 2025 beat Wall Street estimates driven by strong demand for wound care and sterilization products. Revenue grew 0.86% YoY to $8.33B.
Apr 14Solventum reports Q4 2025 ahead of expectations and guides 2026 organic growth of 2-3%, with J.P. Morgan Buy rating.Positive▶
Solventum reported Q4 2025 results ahead of expectations with 2026 guidance for 2-3% organic sales growth and adjusted EPS of $6.40-$6.60. Completed Acera Surgical acquisition. Portfolio simplification includes planned $4.1B sale of Purification & Filtration to Thermo Fisher. J.P. Morgan initiated Buy rating April 8. Consensus rating is Buy with $90.70 target.
Apr 13Solventum opens $200 million R&D facility in Eagan with 1,800+ employees; Chief Accounting Officer to retire.Positive▶
Solventum celebrated the opening of a new $200 million, 250,000-square-foot research and development facility in Eagan on April 1, 2026 with state funding support of $13 million. Chief Accounting Officer Mary Wilcox announced her retirement effective upon successor appointment.
Apr 10Solventum reports Q4 2025 beat with 4% revenue growth; acquired Acera Surgical to expand wound care portfolio.Positive▶
Solventum Corporation reported Q4 2025 results exceeding expectations with $1.998 billion in revenue, up 4% year-over-year. Company completed acquisition of Acera Surgical, expanding MedSurg portfolio into synthetic tissue matrices technology. Analysts maintain Buy rating with $90.7 price target suggesting 39% upside.
Apr 9Solventum Corp beats Q4 earnings with Acera Surgical acquisition integration and $1B share repurchase program approved.Positive▶
Solventum Corporation (SOLV) reported strong Q4 earnings with adjusted EPS of $1.57 (beat $1.50 estimate) and revenue of $2B (+organic growth), highlighting demand for wound care and sterilization products. Company completed acquisition of Acera Surgical in December 2025, expanding medical-surgical solutions into regenerative wound care. Board approved $1 billion share repurchase program. Stock reached $65.28 daily high, with analyst consensus "Buy" rating from 11 analysts targeting $90.7 per share (+39% upside). Solventum achieved Diamond Level Resiliency Badge from Healthcare Industry Resilience Collaborative. 2026 guidance provided for organic growth of 2-3% and adjusted EPS of $6.40-$6.60. Company benefits from healthcare supply chain stability improvements and strategic M&A execution.
Apr 8Solventum opens $200M Eagan R&D facility on second anniversary, expanding innovation capacity.Positive▶
Solventum celebrated second anniversary and opened 250,000-square-foot $200M innovation hub in Eagan on April 2, 2026, consolidating R&D operations for MedSurg, health IT, and diagnostics. Q4 2025 organic sales +3.5%, adjusted EPS $1.57. 2026 guidance: organic sales +2-3% (+3-4% ex SKU exit), adjusted EPS $6.40-$6.60, FCF ~$200M. Acquisition of Acera Surgical (December 2025) expanded synthetic tissue matrices capabilities. Ten analyst consensus "Buy" with $94.11 target, 43.07% upside.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Solventum completed Acera Surgical acquisition; $1B share buyback authorized.Positive▶
Solventum completed Acera Surgical acquisition expanding MedSurg portfolio. Board approved $1B share repurchase. Opened $200M R&D facility in Eagan, MN. Q4 2025 revenue $1.998B (-3.7% reported, +3.5% organic). 2026 guidance: 2-3% organic growth, EPS $6.40-$6.60.
Apr 3No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 2Solventum opens new $200 million R&D facility in Eagan on April 1; Q4 2025 revenue $1.998 billion (+4% YoY); $1B share repurchase approved.Positive▶
On April 1, 2026, Solventum opened a $200 million, 250,000 sq ft R&D facility in Eagan, Minnesota, bringing together the company MedSurg, Dental Solutions, and Health Information Systems operations. Q4 2025 revenue was $1.998 billion (+4% YoY). The Board approved a $1 billion share repurchase program. Analyst consensus is Buy with average price target of $94.11, representing 43% upside from current levels.
Apr 1Solventum reported Q4 2025 organic sales growth of 2.7% and 2026 guidance of $6.40-$6.60 adjusted EPS.Positive▶
Solventum completed Acera Surgical acquisition, expanding MedSurg portfolio. Q4 2025 net sales $1.998B with organic sales up 3.5%, adjusted EPS of $1.57. 2026 guidance: 2.0-3.0% organic growth, $6.40-$6.60 adjusted EPS.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| SOLVSOLVENTUM | $67.06 | -0.45% | +6.5% | 9.7x | 0.77 | $11.7B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| UNHUNITEDHEALTH | $370.09 | -0.11% | +31.7% | 17.9x | 0.41 | $336.5B |
| MRKMERCK | $112.32 | +2.88% | -9.7% | 11.2x | 0.28 | $269.7B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.